

Biotechnology Fund
SCHEDULE OF INVESTMENTS (Unaudited)

June 30, 2018

	Shares	Value
COMMON STOCKS[†] - 99.5%		
Biotechnology - 69.9%		
Amgen, Inc.	92,642	\$ 17,100,787
Gilead Sciences, Inc.	210,480	14,910,403
Biogen, Inc.*	40,978	11,893,455
Celgene Corp.*	148,683	11,808,404
Shire plc ADR	67,020	11,312,976
Vertex Pharmaceuticals, Inc.*	62,445	10,613,152
Regeneron Pharmaceuticals, Inc.*	28,329	9,773,222
Illumina, Inc.*	34,983	9,770,402
Alexion Pharmaceuticals, Inc.*	66,396	8,243,063
BioMarin Pharmaceutical, Inc.*	68,500	6,452,700
Incyte Corp.*	81,605	5,467,535
Seattle Genetics, Inc.*	77,707	5,158,968
Alnylam Pharmaceuticals, Inc.*	46,652	4,594,755
Bio-Rad Laboratories, Inc. — Class A*	15,432	4,452,749
Sage Therapeutics, Inc.*	26,780	4,191,873
Exelixis, Inc.*	191,977	4,131,345
Exact Sciences Corp.*	66,244	3,960,729
Bluebird Bio, Inc.*	25,032	3,928,772
FibroGen, Inc.*	57,820	3,619,532
Loxo Oncology, Inc.*	20,340	3,528,583
United Therapeutics Corp.*	30,406	3,440,439
Ligand Pharmaceuticals, Inc. — Class B*	16,235	3,363,405
Ionis Pharmaceuticals, Inc.*	80,061	3,336,142
Immunomedics, Inc.* ¹	134,870	3,192,373
Ultragenyx Pharmaceutical, Inc.*	38,396	2,951,501
Spark Therapeutics, Inc.*	34,530	2,857,703
Amicus Therapeutics, Inc.*	165,991	2,592,779
Medicines Co.* ¹	69,668	2,556,816
Intercept Pharmaceuticals, Inc.*	29,990	2,516,461
Myriad Genetics, Inc.*	66,696	2,492,430
Blueprint Medicines Corp.*	37,530	2,382,404
Puma Biotechnology, Inc.*	40,060	2,369,549
Spectrum Pharmaceuticals, Inc.*	111,240	2,331,590
ACADIA Pharmaceuticals, Inc.*	143,183	2,186,404
Editas Medicine, Inc.*	55,259	1,979,930
AnaptysBio, Inc.*	26,518	1,883,839
ImmunoGen, Inc.*	184,850	1,798,590
Sangamo Therapeutics, Inc.*	125,280	1,778,976
Radius Health, Inc.* ¹	60,223	1,774,772
Esperion Therapeutics, Inc.* ¹	38,957	1,526,725
Dynavax Technologies Corp.* ¹	98,700	1,505,175
Total Biotechnology		205,731,408
Pharmaceuticals - 25.6%		
AbbVie, Inc.	196,456	18,201,648
Mylan N.V.*	177,390	6,410,875
Sarepta Therapeutics, Inc.*	40,090	5,299,096
Neurocrine Biosciences, Inc.*	46,591	4,577,100
Nektar Therapeutics*	85,605	4,180,092
Jazz Pharmaceuticals plc*	23,900	4,117,970
PRA Health Sciences, Inc.*	40,298	3,762,221
Alkermes plc*	80,618	3,318,237
Agius Pharmaceuticals, Inc.*	38,544	3,246,561
Supernus Pharmaceuticals, Inc.*	48,190	2,884,171
Array BioPharma, Inc.*	167,420	2,809,308
Ironwood Pharmaceuticals, Inc. — Class A*	139,981	2,676,437
TESARO, Inc.* ¹	57,193	2,543,373
Horizon Pharma plc*	149,894	2,482,245
Clovis Oncology, Inc.*	53,217	2,419,777
Global Blood Therapeutics, Inc.*	52,295	2,363,734
Portola Pharmaceuticals, Inc.*	62,185	2,348,727
Pacira Pharmaceuticals, Inc.*	50,539	1,619,775
Total Pharmaceuticals		75,261,347
Healthcare-Services - 2.4%		
Charles River Laboratories International, Inc.*	31,768	3,566,276
Syneos Health, Inc.*	72,630	3,406,347
Total Healthcare-Services		6,972,623
Healthcare-Products - 1.6%		
Bio-Techne Corp.	23,522	3,480,080
MiMedx Group, Inc.* ¹	222,710	1,423,117
Total Healthcare-Products		4,903,197
Total Common Stocks (Cost \$168,622,275)		292,868,575
RIGHTS^{†††} - 0.0%		
Dyax Corp.* ⁵	167,165	—
Clinical Data, Inc.* ⁵	24,000	—
Total Rights (Cost \$—)		—
	Face Amount	
REPURCHASE AGREEMENTS^{††,2} - 0.7%		
JPMorgan Chase & Co. issued 06/29/18 at 2.10% due 07/02/18	\$ 1,152,458	1,152,458
Barclays Capital issued 06/29/18 at 2.07% due 07/02/18	565,912	565,912
Bank of America Merrill Lynch issued 06/29/18 at 2.08% due 07/02/18	377,274	377,274
Total Repurchase Agreements (Cost \$2,095,644)		2,095,644
	Shares	
SECURITIES LENDING COLLATERAL^{†,3} - 2.9%		
Money Market Fund		
First American Government Obligations Fund — Class Z, 1.77% ⁴	8,568,882	8,568,882
Total Securities Lending Collateral (Cost \$8,568,882)		8,568,882
Total Investments - 103.1% (Cost \$179,286,801)		\$ 303,533,101
Other Assets & Liabilities, net - (3.1)%		(9,211,240)
Total Net Assets - 100.0%		\$ 294,321,861

Biotechnology Fund
SCHEDULE OF INVESTMENTS (Unaudited)

June 30, 2018

-
- * *Non-income producing security.*
 - † *Value determined based on Level 1 inputs.*
 - †† *Value determined based on Level 2 inputs.*
 - ††† *Value determined based on Level 3 inputs.*
 - 1 *All or portion of this security is on loan at June 30, 2018.*
 - 2 *Repurchase Agreements.*
 - 3 *Securities lending collateral.*
 - 4 *Rate indicated is the 7 day yield as of June 30, 2018.*
 - 5 *Security was fair valued by the Valuation Committee at June 30, 2018. The total market value of fair valued securities amounts to \$0, (cost \$0) or 0.0% of total net assets.*

ADR — American Depositary Receipt
plc — Public Limited Company